{
    "ticker": "NBTX",
    "name": "Nanobiotix S.A.",
    "description": "Nanobiotix S.A. is an innovative biotechnology company focused on developing and commercializing nanomedicine products for cancer treatment. Founded in 2003 and headquartered in Paris, France, Nanobiotix specializes in the design of nanoparticles that can enhance the effectiveness of radiotherapy, offering a novel approach to cancer therapy. The company's flagship product, NBTX-101, is a proprietary formulation of nanoparticles that aims to improve radiation therapy outcomes by increasing the absorption of radiation by tumor cells while minimizing damage to surrounding healthy tissue. This technology represents a significant advancement in personalized medicine, as it has the potential to enhance the efficacy of existing treatment protocols and improve patient quality of life. Nanobiotix is actively engaged in clinical trials to validate its products and expand its therapeutic applications, focusing on solid tumors and various treatment combinations. With a strong commitment to research and development, Nanobiotix partners with leading academic institutions and cancer treatment centers worldwide to advance its innovative therapies. The company's mission is to transform the landscape of cancer treatment through cutting-edge nanotechnology and to provide hope to patients facing this challenging disease.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Paris, France",
    "founded": "2003",
    "website": "https://www.nanobiotix.com",
    "ceo": "Laurent Levy",
    "social_media": {
        "twitter": "https://twitter.com/Nanobiotix",
        "linkedin": "https://www.linkedin.com/company/nanobiotix"
    },
    "investor_relations": "https://www.nanobiotix.com/investors/",
    "key_executives": [
        {
            "name": "Laurent Levy",
            "position": "CEO"
        },
        {
            "name": "Sophie G. V. T. de Launoit",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Nanomedicine Products",
            "products": [
                "NBTX-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Nanobiotix S.A. | Pioneering Nanomedicine for Cancer Treatment",
        "meta_description": "Explore Nanobiotix S.A., a leader in nanomedicine focused on enhancing cancer treatment through innovative nanoparticle technology.",
        "keywords": [
            "Nanobiotix",
            "Nanomedicine",
            "Cancer Treatment",
            "NBTX-101",
            "Radiotherapy",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Nanobiotix known for?",
            "answer": "Nanobiotix is known for its groundbreaking nanomedicine products aimed at improving cancer treatment, particularly through enhanced radiotherapy."
        },
        {
            "question": "Who is the CEO of Nanobiotix?",
            "answer": "Laurent Levy is the CEO of Nanobiotix S.A."
        },
        {
            "question": "Where is Nanobiotix headquartered?",
            "answer": "Nanobiotix is headquartered in Paris, France."
        },
        {
            "question": "What is Nanobiotix's main product?",
            "answer": "Nanobiotix's main product is NBTX-101, a nanoparticle formulation designed to improve the effectiveness of radiotherapy."
        },
        {
            "question": "When was Nanobiotix founded?",
            "answer": "Nanobiotix was founded in 2003."
        }
    ],
    "competitors": [
        "CRIS",
        "NVS",
        "AMGN"
    ],
    "related_stocks": [
        "AAPL",
        "MSFT",
        "GILD",
        "BMY"
    ]
}